In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study
Background Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and radioactive iodine-resistant thyroid carcinoma. Notably, glucose transporters sodium-glucose cotransporter 2 (SGLT2) and glucose trans...
Saved in:
| Main Authors: | Wenyu Du, Zihan Liu, Zhi Wang, Xin Zhou, Zhanjun Dong, Ying Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2025-07-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/19662.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats
by: Li Y, et al.
Published: (2025-07-01) -
Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes
by: Shujun Zhang, et al.
Published: (2024-11-01) -
GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma
by: Shiwen Ma, et al.
Published: (2024-12-01) -
ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma
by: Ying Shi, et al.
Published: (2023-02-01) -
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01)